ADA 2014: Diabetes Players Move Closer To An Artificial Pancreas
Executive Summary
The quest to bring an artificial pancreas to market has taken some giant steps forward recently, as major players continue to produce impressive data from clinical studies that measure the use of various insulin pumps, continuous glucose monitors (CGMs), and algorithms. Improvements in CGM sensor technology have helped move AP research, and competition is proving to be a driving force on the road to producing a commercial product that could be within two or three years from reaching the market.
You may also be interested in...
Diabetes Market Sees Advances In CGMs, Artificial Pancreas Systems, And Connectivity
The focus of the diabetes market is firmly on the development of an artificial pancreas, now within two or three years from becoming commercialized, and progress is going so well that several companies are in line to release a product. Meanwhile, digital health is increasingly playing a major role in diabetes care, and device manufacturers are investing in connectivity solutions to satisfy patient and consumer needs.
Abbott Earns CE Mark For FreeStyle Libre Bloodless Glucose Monitor
FreeStyle Libre reads glucose levels through a interstitial fluid sensor on the back of the patient’s arm, but unlike current continuous glucose monitors does not require finger-stick calibrations.
Apps Ahead For Diabetes: Q&A With DexCom’s Terry Gregg
Continuous glucose monitor developer DexCom is staking its future on an app-based platform for sensor-insulin pump systems. CEO Terrance Gregg offers an update on the company’s efforts, his thoughts on the space and the growing interest in glucose monitoring by big tech firms like Apple and Google.